BEFORE

The Materials We Received

The company’s story was spread across previous decks, working documents, clinical-data exports, scientific references, software screenshots, AI-generated layouts, and notes from different contributors. Each source contained an important part of the story. Together, they still did not give investors a clear path from the science to the investment opportunity.

Pain-Points

Scattered source material
Dense scientific evidence
No clear investor progression
Inconsistent visual language

Important information lived across multiple files, formats, and working versions.

Scattered source materials provided before the pre-IPO biotech presentation redesign

The science was credible but difficult for a broader investment audience to follow quickly.

Dense scientific evidence slide from the original biotech company overview deck

The unmet need, mechanism, clinical evidence, market opportunity, and milestones did not yet connect as one story.

Disconnected investor narrative in the original pre-IPO company presentation

Scientific diagrams, clinical charts, and company slides looked like they came from
different presentations.

Inconsistent visual styles across the biotech company's original presentation materials
THE PROCESS

From Scattered Evidence to a Structured Story

01

Consolidate

Every document, chart, screenshot, and working slide, into one source.

02

Map

Need → mechanism → evidence → market → catalysts.

03

Systemize

One visual language across light and dark slides.

04

Visualize

Custom science and clinical data, built for the room.

SOLUTION

25 Slides. 4 Clear Chapters

Not a gallery of disconnected slides. A deliberate progression built around how a pre-IPO opportunity is evaluated.

CHAPTER 01 · THE NEED

Why the 80% are left behind

The unmet need and the scale of the opportunity current immunotherapy leaves behind.

←→
Cover slide of the Bloom BioSciences pre-IPO company overview deck introducing PRX-401 oral immunotherapy for cold tumorsInvestment thesis slide from the biotech company overview presentation showing five pillars from unmet need to de-risked timingCompany at a glance slide from the pre-IPO biotech deck with lead asset, interim ORR, Series C funding, and IPO timelineProblem slide from the biotech investor presentation showing checkpoint immunotherapy fails 80 percent of cold tumor patientsCustom scientific illustration explaining why T cells die inside cold tumors, designed for the pre-IPO overview deck
‹›
CHAPTER 02 · THE SCIENCE

How PRX-401 rebuilds the response

Root cause, mechanism, and the lead molecule, drawn so a generalist can follow the biology.

←→
Solution slide from the biotech overview deck showing how PRX-401 restores tryptophan and revives T cells in three stepsCustom mechanism illustration comparing tumor response with and without PRX-401 in the pre-IPO biotech presentationComparison slide from the biotech investor deck explaining why prior IDO inhibitor programs failed and how dual dosing differsLead molecule slide from the pre-IPO company overview presenting PRX-401 as the only oral dual IDO1 TDO2 inhibitor in the clinic
‹›
CHAPTER 03 · THE EVIDENCE

The data behind the thesis

Study design, results, durability, and safety — and the market and competition the data speaks to.

←→
Duration of response swimmer chart from the biotech investor deck showing durable responses with a median of 8.4 monthsPhase 2 clinical study design slide from the pre-IPO biotech presentation with eligibility, trial arms, and endpointsInterim Phase 2 data slide with best tumor change waterfall chart showing 34 percent ORR in the biotech overview deckTranslational evidence chart from the biotech company overview showing tumor response tracking depth of pathway suppressionSafety profile slide from the pre-IPO deck comparing adverse events with checkpoint monotherapy and zero dose-limiting toxicityMarket opportunity slide from the biotech investor presentation sizing the unlocked 80 percent of checkpoint non-respondersValue creation slide with a bottoms-up revenue build to US peak sales in the pre-IPO company overview deckCompetitive landscape table from the biotech overview deck comparing PRX-401 with bispecifics, CAR-T, and ADC therapies
‹›
CHAPTER 04 · THE PATH

From evidence to IPO

The moat, the partners, the team, and the timing that leads to a listing.

←→
Intellectual property slide from the pre-IPO biotech deck showing a layered exclusivity runway with protection into the 2040sRegulatory strategy slide from the biotech overview deck comparing accelerated approval and traditional BLA pathwaysStrategic partnership slide from the pre-IPO presentation showing the anti-PD-1 combination collaboration with a leading IO partnerLeadership and advisors slide from the biotech investor deck with prior FDA approvals, IPOs led, and M&A track recordFinancials slide from the pre-IPO company overview showing Series C allocation funding every value-creating event before the IPOKey milestones timeline from the biotech deck showing topline data landing one quarter ahead of the Nasdaq IPOPipeline slide from the biotech overview presentation showing one molecule targeting the two largest checkpoint-resistant tumor typesClosing slide of the Bloom BioSciences pre-IPO overview deck with the mission to make immunotherapy work for patients it fails
‹›
DESIGN SYSTEM

Two Visual Modes. One Coherent System

The themes are functional, not decorative. Flip the toggle and watch the same slides switch roles.

DarkLight
Dark carries the biologyMechanism of action, differentiation, and the high-impact scientific moments where the room should lean in.
Dark theme slide showing how the immune response is rebuilt step by step with PRX-401 in the biotech deck design systemDark theme root cause slide illustrating why T cells die inside cold tumors from the pre-IPO presentation design systemDark theme lead molecule slide presenting the oral dual IDO1 TDO2 inhibitor in the biotech overview deck design system
Light carries the evaluationClinical data, market evidence, financials, and milestones, where an investor needs to scan, compare, and note.
Light theme translational evidence slide showing tumor response tracking pathway suppression in the biotech deck design systemLight theme Phase 2 interim data slide with 34 percent ORR waterfall chart from the pre-IPO presentation design systemLight theme value creation slide with the bottoms-up US peak sales build from the biotech overview deck design system
CUSTOM ILLUSTRATIONS

Textbook-Level Science, Redrawn in Bloom's Visual Language

Instead of inconsistent textbook diagrams and generic medical imagery, we built custom scientific illustrations from the ground up. Each one simplifies the biology for a presentation setting while preserving the relationships the audience needs to understand.

Original textbook-style diagram of cold and hot tumors used as reference before the custom scientific illustration redesign
Animated redraw of the tumor microenvironment illustration in Bloom's custom visual language for the pre-IPO deck
CONCLUSION

One Deck. One Narrative.
Ready for the Room

Bloom started with strong science and valuable clinical evidence spread across multiple formats. The final company overview presentation brings everything into one connected investor journey. The science is easier to understand, the clinical signal is easier to evaluate, and the commercial opportunity arrives in the same consistent visual language.

25 Slides

One complete pre-IPO company overview, presentable live and readable as a leave-behind.

2 Visual Modes

A coordinated dark and light system, each with a defined communication role.

Custom Illustration

Purpose-built scientific illustrations created for the company’s biology and presentation story.

One Clear Flow

From unmet need and mechanism to evidence, market opportunity, and IPO catalysts.